Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 14 peer-reviewed journal articles Updated
Hematology

Biology and Diagnosis: The KIT Mutation and WHO Criteria

At a Glance

Indolent systemic mastocytosis (ISM) is primarily driven by the KIT D816V mutation, which causes mast cells to overproduce and accumulate. Diagnosis requires meeting specific WHO criteria, such as finding dense mast cell clusters in the bone marrow, while confirming there is no active organ damage.

Understanding the biology of Indolent Systemic Mastocytosis (ISM) helps demystify why your body is behaving this way. At its core, ISM is a “clonal” disorder, meaning it starts with a specific genetic change in a single cell that then copies itself [1].

The “On Switch”: The KIT D816V Mutation

In over 90% of people with ISM, the disease is driven by a specific mutation called KIT D816V [2].

Imagine the KIT receptor on the surface of a mast cell as a light switch that controls growth. In a healthy person, this switch only turns “on” when the body sends a specific signal [3]. However, the KIT D816V mutation breaks the switch, locking it in the “on” position permanently [3]. This causes mast cells to:

  • Multiply when they shouldn’t [4].
  • Survive much longer than normal cells [5].
  • Cluster together in organs like the bone marrow [6].

How Doctors Confirm the Diagnosis

To formally diagnose Systemic Mastocytosis (SM), the World Health Organization (WHO) requires a specific combination of criteria. Doctors look for 1 Major criterion and 1 Minor criterion, or 3 Minor criteria [6].

The Major Criterion

  • Multifocal Dense Aggregates: During a bone marrow biopsy, a pathologist looks for dense clusters of 15 or more mast cells grouped together [6][7].

The Four Minor Criteria

  1. Atypical Shape: More than 25% of the mast cells are “spindle-shaped” or look irregular rather than round [6].
  2. The Mutation: Detection of the KIT D816V mutation in the blood or bone marrow [8].
  3. Surface Markers: Mast cells display “abnormal” proteins on their surface, specifically CD25, CD2, and/or CD30 [6][9].
  4. High Tryptase: A blood test showing a serum tryptase level persistently above 20 ng/mL [6].

B-Findings vs. C-Findings: Defining “Indolent”

The most important part of your diagnosis is the word “Indolent.” This is determined by looking for “B-findings” and “C-findings” [10].

  • B-Findings (Burden): these indicate a high number of mast cells in the body (a high “burden”) but no organ damage. Examples include a very high tryptase level (>200 ng/mL) or an enlarged spleen that still functions normally [10][11].
  • C-Findings (Damage): These indicate that mast cells are actively damaging an organ. This includes severe anemia, liver failure, or bone fractures [10][12].

By definition, Indolent Systemic Mastocytosis (ISM) means you have zero C-findings [13]. You may have 0 or 1 B-finding, but if you had 2 or more, the diagnosis would shift to “Smoldering” SM [14].

Pathology Report Checklist

When reviewing your records, ensure your pathology report includes these essential elements to confirm a complete workup [9]:

  • [ ] Tryptase Staining: To count the mast cell clusters.
  • [ ] CD117 Staining: To identify the mast cells.
  • [ ] CD25 / CD2 / CD30 Status: To check for abnormal surface proteins.
  • [ ] KIT D816V Mutation Analysis: To confirm the genetic “driver.”
  • [ ] Morphology Description: To note if cells are “spindle-shaped.”

Common questions in this guide

What is the KIT D816V mutation?
The KIT D816V mutation is a genetic change found in over 90% of people with indolent systemic mastocytosis. It acts like a broken "on switch," causing mast cells to constantly multiply and survive longer than normal healthy cells.
How do doctors diagnose systemic mastocytosis?
Doctors use criteria set by the World Health Organization to confirm a diagnosis. This requires finding a major criterion, like dense clusters of mast cells in your bone marrow, combined with minor criteria such as the KIT mutation, abnormal cell shapes, or high tryptase levels.
What does "indolent" mean in systemic mastocytosis?
The term indolent means that while you have an excess of mast cells, they are not actively causing damage to your organs. Doctors confirm this by verifying you have zero "C-findings," which are clinical indicators of severe organ dysfunction like liver failure or severe anemia.
What is the difference between B-findings and C-findings?
B-findings indicate a high "burden" or amount of mast cells in your body, such as a very high tryptase level, but without organ damage. C-findings mean the mast cells are actively causing damage to your organs, which would change your diagnosis from indolent to a more advanced form.
What should I look for on my mastocytosis pathology report?
Your report should confirm if there are "multifocal dense aggregates" of 15 or more mast cells. It should also include results for tryptase and CD117 staining, tests for surface proteins like CD25 or CD30, and confirmation of your KIT D816V mutation status.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Does my bone marrow report specifically mention 'multifocal dense aggregates' of 15 or more mast cells?
  2. 2.What was the 'Variant Allele Frequency' (VAF) for my KIT D816V mutation? How does this number reflect my overall disease burden?
  3. 3.Which specific minor criteria did I meet to confirm my systemic diagnosis?
  4. 4.Based on my scans and blood work, can you confirm I have zero 'C-findings'?
  5. 5.Were my mast cells tested for the CD25 or CD30 markers, and was that done via flow cytometry or immunohistochemistry?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (14)
  1. 1

    Diarrhea-predominant irritable bowel syndrome as a masquerade for systemic mastocytosis: review article and illustrating case report.

    Aljabry M

    Archives of medical science : AMS 2024; (20(4)):1063-1068 doi:10.5114/aoms/176943.

    PMID: 39439696
  2. 2

    KIT Mutations and Other Genetic Defects in Mastocytosis: Implications for Disease Pathology and Targeted Therapies.

    Chantran Y, Valent P, Arock M

    Immunology and allergy clinics of North America 2023; (43(4)):651-664 doi:10.1016/j.iac.2023.04.008.

    PMID: 37758404
  3. 3

    A change in structural integrity of c-Kit mutant D816V causes constitutive signaling.

    Raghav PK, Singh AK, Gangenahalli G

    Mutation research 2018; (808()):28-38 doi:10.1016/j.mrfmmm.2018.02.001.

    PMID: 29482074
  4. 4

    Novel KIT mutation, D816_N819delinsll, in a patient with systemic mastocytosis: a case report.

    Juratli HA, Wassmer H, Juskevicius D, et al.

    Virchows Archiv : an international journal of pathology 2025; doi:10.1007/s00428-025-04237-9.

    PMID: 40892237
  5. 5

    Tumor necrosis factor α promotes clonal dominance of KIT D816V+ cells in mastocytosis: role of survivin and impact on prognosis.

    Greiner G, Witzeneder N, Klein K, et al.

    Blood 2024; (143(11)):1006-1017 doi:10.1182/blood.2023020515.

    PMID: 38142424
  6. 6

    Diagnosing Systemic Mastocytosis: State of the Art.

    Rets A, George TI

    International journal of laboratory hematology 2025; doi:10.1111/ijlh.70011.

    PMID: 41058066
  7. 7

    Systemic mastocytosis in adults: 2021 Update on diagnosis, risk stratification and management.

    Pardanani A

    American journal of hematology 2021; (96(4)):508-525 doi:10.1002/ajh.26118.

    PMID: 33524167
  8. 8

    Systemic Mastocytosis and Other Entities Involving Mast Cells: A Practical Review and Update.

    El Hussein S, Chifotides HT, Khoury JD, et al.

    Cancers 2022; (14(14)) doi:10.3390/cancers14143474.

    PMID: 35884535
  9. 9

    Impact of centralized evaluation of bone marrow histology in systemic mastocytosis.

    Jawhar M, Schwaab J, Horny HP, et al.

    European journal of clinical investigation 2016; (46(5)):392-7 doi:10.1111/eci.12607.

    PMID: 26914980
  10. 10

    Management of Advanced Systemic Mastocytosis and Associated Myeloid Neoplasms.

    Tashi T, Deininger MW

    Immunology and allergy clinics of North America 2023; (43(4)):723-741 doi:10.1016/j.iac.2023.04.009.

    PMID: 37758409
  11. 11

    Mastocytosis: the puzzling clinical spectrum and challenging diagnostic aspects of an enigmatic disease.

    Gülen T, Hägglund H, Dahlén B, Nilsson G

    Journal of internal medicine 2016; (279(3)):211-28 doi:10.1111/joim.12410.

    PMID: 26347286
  12. 12

    Aggressive Systemic Mastocytosis in Association with Pure Red Cell Aplasia.

    Karam D, Swiatkowski S, Ravipati M, Agrawal B

    Case reports in hematology 2018; (2018()):6928571 doi:10.1155/2018/6928571.

    PMID: 30069418
  13. 13

    Relevant updates in systemic mastocytosis.

    Coltoff A, Mascarenhas J

    Leukemia research 2019; (81()):10-18 doi:10.1016/j.leukres.2019.04.001.

    PMID: 30978435
  14. 14

    Indolent systemic mastocytosis and aleukemic mast cell leukemia: Subtle diagnostic differences with distinct management approaches.

    Paiva ML, Yumeen S, Saliba E, DiMarco C

    JAAD case reports 2023; (36()):63-66 doi:10.1016/j.jdcr.2023.04.009.

    PMID: 37250010

This page explains Indolent Systemic Mastocytosis (ISM) biology and diagnostic criteria for educational purposes. Always consult your hematologist or oncologist to interpret your specific pathology report and test results.

Get notified when new evidence is published on Indolent systemic mastocytosis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.